Spectrum Pharmaceuticals Competitors

Amgen (NASDAQ:AMGN) and Spectrum Pharmaceuticals (NASDAQ:SPPI) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, risk, valuation and institutional ownership.

Volatility & Risk

Amgen has a beta of 0.76, meaning that its share price is 24% less volatile than the S&P 500. Comparatively, Spectrum Pharmaceuticals has a beta of 2.51, meaning that its share price is 151% more volatile than the S&P 500.

Insider and Institutional Ownership

75.2% of Amgen shares are held by institutional investors. Comparatively, 63.6% of Spectrum Pharmaceuticals shares are held by institutional investors. 0.4% of Amgen shares are held by company insiders. Comparatively, 5.0% of Spectrum Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Amgen and Spectrum Pharmaceuticals' net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of recent recommendations for Amgen and Spectrum Pharmaceuticals, as provided by MarketBeat.

Amgen presently has a consensus price target of $261.1429, suggesting a potential upside of 0.77%. Spectrum Pharmaceuticals has a consensus price target of $9.75, suggesting a potential upside of 235.05%. Given Spectrum Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Spectrum Pharmaceuticals is more favorable than Amgen.

Earnings and Valuation

This table compares Amgen and Spectrum Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Amgen has higher revenue and earnings than Spectrum Pharmaceuticals. Spectrum Pharmaceuticals is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Summary

Amgen beats Spectrum Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

Spectrum Pharmaceuticals (NASDAQ:SPPI) and Gilead Sciences (NASDAQ:GILD) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.

Volatility & Risk

Spectrum Pharmaceuticals has a beta of 2.51, indicating that its share price is 151% more volatile than the S&P 500. Comparatively, Gilead Sciences has a beta of 0.51, indicating that its share price is 49% less volatile than the S&P 500.

Insider and Institutional Ownership

63.6% of Spectrum Pharmaceuticals shares are owned by institutional investors. Comparatively, 76.4% of Gilead Sciences shares are owned by institutional investors. 5.0% of Spectrum Pharmaceuticals shares are owned by company insiders. Comparatively, 0.1% of Gilead Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Spectrum Pharmaceuticals and Gilead Sciences' net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Spectrum Pharmaceuticals and Gilead Sciences, as reported by MarketBeat.com.

Spectrum Pharmaceuticals currently has a consensus target price of $9.75, suggesting a potential upside of 235.05%. Gilead Sciences has a consensus target price of $97.68, suggesting a potential upside of 47.15%. Given Spectrum Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Spectrum Pharmaceuticals is more favorable than Gilead Sciences.

Earnings & Valuation

This table compares Spectrum Pharmaceuticals and Gilead Sciences' revenue, earnings per share (EPS) and valuation.

Gilead Sciences has higher revenue and earnings than Spectrum Pharmaceuticals. Spectrum Pharmaceuticals is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Summary

Gilead Sciences beats Spectrum Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Spectrum Pharmaceuticals (NASDAQ:SPPI) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.

Volatility & Risk

Spectrum Pharmaceuticals has a beta of 2.51, indicating that its share price is 151% more volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500.

Insider and Institutional Ownership

63.6% of Spectrum Pharmaceuticals shares are owned by institutional investors. Comparatively, 92.2% of Vertex Pharmaceuticals shares are owned by institutional investors. 5.0% of Spectrum Pharmaceuticals shares are owned by company insiders. Comparatively, 0.7% of Vertex Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Spectrum Pharmaceuticals and Vertex Pharmaceuticals' net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Spectrum Pharmaceuticals and Vertex Pharmaceuticals, as reported by MarketBeat.com.

Spectrum Pharmaceuticals currently has a consensus target price of $9.75, suggesting a potential upside of 235.05%. Vertex Pharmaceuticals has a consensus target price of $293.2083, suggesting a potential upside of 33.18%. Given Spectrum Pharmaceuticals' higher possible upside, analysts clearly believe Spectrum Pharmaceuticals is more favorable than Vertex Pharmaceuticals.

Earnings & Valuation

This table compares Spectrum Pharmaceuticals and Vertex Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Vertex Pharmaceuticals has higher revenue and earnings than Spectrum Pharmaceuticals. Spectrum Pharmaceuticals is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Vertex Pharmaceuticals beats Spectrum Pharmaceuticals on 12 of the 15 factors compared between the two stocks.

Regeneron Pharmaceuticals (NASDAQ:REGN) and Spectrum Pharmaceuticals (NASDAQ:SPPI) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, valuation, risk, profitability, analyst recommendations, earnings and institutional ownership.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Regeneron Pharmaceuticals and Spectrum Pharmaceuticals, as reported by MarketBeat.com.

Regeneron Pharmaceuticals currently has a consensus price target of $644.1739, indicating a potential upside of 27.71%. Spectrum Pharmaceuticals has a consensus price target of $9.75, indicating a potential upside of 235.05%. Given Spectrum Pharmaceuticals' higher possible upside, analysts plainly believe Spectrum Pharmaceuticals is more favorable than Regeneron Pharmaceuticals.

Risk and Volatility

Regeneron Pharmaceuticals has a beta of 0.3, meaning that its stock price is 70% less volatile than the S&P 500. Comparatively, Spectrum Pharmaceuticals has a beta of 2.51, meaning that its stock price is 151% more volatile than the S&P 500.

Insider & Institutional Ownership

85.0% of Regeneron Pharmaceuticals shares are owned by institutional investors. Comparatively, 63.6% of Spectrum Pharmaceuticals shares are owned by institutional investors. 11.8% of Regeneron Pharmaceuticals shares are owned by company insiders. Comparatively, 5.0% of Spectrum Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Regeneron Pharmaceuticals and Spectrum Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Regeneron Pharmaceuticals has higher revenue and earnings than Spectrum Pharmaceuticals. Spectrum Pharmaceuticals is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Regeneron Pharmaceuticals and Spectrum Pharmaceuticals' net margins, return on equity and return on assets.

Summary

Regeneron Pharmaceuticals beats Spectrum Pharmaceuticals on 13 of the 15 factors compared between the two stocks.

Spectrum Pharmaceuticals (NASDAQ:SPPI) and Biogen (NASDAQ:BIIB) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, valuation, analyst recommendations, institutional ownership, profitability and dividends.

Profitability

This table compares Spectrum Pharmaceuticals and Biogen's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Spectrum Pharmaceuticals and Biogen's gross revenue, earnings per share and valuation.

Biogen has higher revenue and earnings than Spectrum Pharmaceuticals. Spectrum Pharmaceuticals is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Spectrum Pharmaceuticals has a beta of 2.51, suggesting that its share price is 151% more volatile than the S&P 500. Comparatively, Biogen has a beta of 0.53, suggesting that its share price is 47% less volatile than the S&P 500.

Institutional and Insider Ownership

63.6% of Spectrum Pharmaceuticals shares are held by institutional investors. Comparatively, 83.5% of Biogen shares are held by institutional investors. 5.0% of Spectrum Pharmaceuticals shares are held by insiders. Comparatively, 0.5% of Biogen shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current recommendations and price targets for Spectrum Pharmaceuticals and Biogen, as provided by MarketBeat.com.

Spectrum Pharmaceuticals presently has a consensus target price of $9.75, indicating a potential upside of 235.05%. Biogen has a consensus target price of $303.3103, indicating a potential upside of 11.02%. Given Spectrum Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Spectrum Pharmaceuticals is more favorable than Biogen.

Summary

Biogen beats Spectrum Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Alexion Pharmaceuticals (NASDAQ:ALXN) and Spectrum Pharmaceuticals (NASDAQ:SPPI) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, analyst recommendations, risk, earnings and dividends.

Profitability

This table compares Alexion Pharmaceuticals and Spectrum Pharmaceuticals' net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Alexion Pharmaceuticals and Spectrum Pharmaceuticals, as reported by MarketBeat.

Alexion Pharmaceuticals currently has a consensus price target of $153.4286, indicating a potential downside of 7.87%. Spectrum Pharmaceuticals has a consensus price target of $9.75, indicating a potential upside of 235.05%. Given Spectrum Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Spectrum Pharmaceuticals is more favorable than Alexion Pharmaceuticals.

Valuation and Earnings

This table compares Alexion Pharmaceuticals and Spectrum Pharmaceuticals' revenue, earnings per share and valuation.

Alexion Pharmaceuticals has higher revenue and earnings than Spectrum Pharmaceuticals. Spectrum Pharmaceuticals is trading at a lower price-to-earnings ratio than Alexion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

87.3% of Alexion Pharmaceuticals shares are owned by institutional investors. Comparatively, 63.6% of Spectrum Pharmaceuticals shares are owned by institutional investors. 4.0% of Alexion Pharmaceuticals shares are owned by insiders. Comparatively, 5.0% of Spectrum Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Volatility & Risk

Alexion Pharmaceuticals has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500. Comparatively, Spectrum Pharmaceuticals has a beta of 2.51, meaning that its share price is 151% more volatile than the S&P 500.

Summary

Alexion Pharmaceuticals beats Spectrum Pharmaceuticals on 11 of the 15 factors compared between the two stocks.